Jackson Wealth Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 3.6% during the second quarter, Holdings Channel reports. The institutional investor owned 51,114 shares of the biopharmaceutical company’s stock after buying an additional 1,785 shares during the period. Jackson Wealth Management LLC’s holdings in Pfizer were worth $1,800,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Stelac Advisory Services LLC purchased a new position in shares of Pfizer during the second quarter valued at $110,000. Catamount Wealth Management increased its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Commonwealth Financial Services LLC increased its position in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares during the period. Stuart Chaussee & Associates Inc. increased its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Finally, Financial Management Professionals Inc. increased its position in shares of Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 993 shares during the period. Institutional investors own 69.66% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.31% on Friday, hitting $32.66. 15,569,339 shares of the company’s stock traded hands. The company has a market cap of $198.10 billion, a price-to-earnings ratio of 28.95 and a beta of 0.86. The firm’s 50-day moving average price is $34.02 and its 200 day moving average price is $34.27. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same period in the previous year, the business posted $0.56 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.67%. Pfizer’s dividend payout ratio is 95.24%.
Several brokerages have recently weighed in on PFE. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 target price for the company. in a research note on Thursday. Jefferies Group downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price objective for the company from $39.00 to $36.00 in a research note on Thursday. Argus reiterated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research note on Tuesday, October 4th. Bank of America Corp. reiterated a “buy” rating and set a $40.00 price objective on shares of Pfizer in a research note on Tuesday, September 27th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a research note on Monday, September 26th. Eleven research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.